NURS 5334 ADVANCED
PHARMACOTHERAPEUTICS PRACTICE
EXAM QUESTIONS WITH CORRECT
ANSWERS (LATEST ), (A+
GUARANTEE).
1. Which of the following describes the ‘first-pass effect’ in pharmacokinetics?
A. The initial distribution of a drug to highly perfused organs.
B. The binding of a drug to plasma proteins during its first circuit through the blood.
C. The rapid excretion of a drug by the kidneys immediately after administration.
D. The metabolic reduction of a drug’s concentration before it reaches systemic circulation.
Answer: D
Conceptual Explanation: The first-pass effect occurs when a drug is metabolized in the
liver or gut wall before reaching systemic circulation, significantly reducing its
bioavailability.
2. A patient is prescribed a drug that is a known substrate of the CYP3A4 enzyme. If the
patient starts consuming grapefruit juice daily, what is the likely outcome?
A. Decreased plasma concentration of the drug due to enzyme induction.
B. Decreased drug efficacy due to impaired absorption.
,C. No change, as grapefruit juice only affects CYP2D6.
D. Increased plasma concentration of the drug due to enzyme inhibition.
Answer: D
Conceptual Explanation: Grapefruit juice is a potent inhibitor of CYP3A4. Inhibiting the
enzyme leads to decreased metabolism and increased levels of the substrate drug, raising
the risk of toxicity.
3. Which pharmacokinetic parameter is most useful in determining the dosing interval for a
drug?
A. Volume of distribution (Vd)
B. Bioavailability (F)
C. Peak plasma concentration (Cmax)
D. Elimination half-life (t1/2)
Answer: D
Conceptual Explanation: The elimination half-life determines how long it takes for the
drug concentration to reduce by half, which guides how often the drug should be
administered to maintain therapeutic levels.
4. A drug with a narrow therapeutic index (NTI) requires which of the following clinical
interventions?
A. Frequent therapeutic drug monitoring (TDM).
, B. Dosing only on an as-needed (PRN) basis.
C. Administration only via the intravenous route.
D. Strict avoidance of all generic formulations.
Answer: A
Conceptual Explanation: NTI drugs have a small window between therapeutic and toxic
doses; therefore, monitoring blood levels is essential to ensure safety and efficacy.
5. In a patient with a Creatinine Clearance (CrCl) of 25 mL/min, the provider should consider
which adjustment for a renally excreted drug?
A. Decrease the dose or lengthen the dosing interval.
B. Increase the dose to compensate for poor absorption.
C. Switch to an oral route to slow systemic entry.
D. No adjustment is necessary until CrCl is below 15 mL/min.
Answer: A
Conceptual Explanation: Decreased renal function reduces the clearance of drugs
eliminated by the kidneys, necessitating dose reductions or increased intervals to prevent
accumulation and toxicity.
6. What is the mechanism of action of ACE inhibitors in the treatment of hypertension?
A. Inhibiting the conversion of Angiotensin I to Angiotensin II.
B. Blocking the binding of Angiotensin II to AT1 receptors.
PHARMACOTHERAPEUTICS PRACTICE
EXAM QUESTIONS WITH CORRECT
ANSWERS (LATEST ), (A+
GUARANTEE).
1. Which of the following describes the ‘first-pass effect’ in pharmacokinetics?
A. The initial distribution of a drug to highly perfused organs.
B. The binding of a drug to plasma proteins during its first circuit through the blood.
C. The rapid excretion of a drug by the kidneys immediately after administration.
D. The metabolic reduction of a drug’s concentration before it reaches systemic circulation.
Answer: D
Conceptual Explanation: The first-pass effect occurs when a drug is metabolized in the
liver or gut wall before reaching systemic circulation, significantly reducing its
bioavailability.
2. A patient is prescribed a drug that is a known substrate of the CYP3A4 enzyme. If the
patient starts consuming grapefruit juice daily, what is the likely outcome?
A. Decreased plasma concentration of the drug due to enzyme induction.
B. Decreased drug efficacy due to impaired absorption.
,C. No change, as grapefruit juice only affects CYP2D6.
D. Increased plasma concentration of the drug due to enzyme inhibition.
Answer: D
Conceptual Explanation: Grapefruit juice is a potent inhibitor of CYP3A4. Inhibiting the
enzyme leads to decreased metabolism and increased levels of the substrate drug, raising
the risk of toxicity.
3. Which pharmacokinetic parameter is most useful in determining the dosing interval for a
drug?
A. Volume of distribution (Vd)
B. Bioavailability (F)
C. Peak plasma concentration (Cmax)
D. Elimination half-life (t1/2)
Answer: D
Conceptual Explanation: The elimination half-life determines how long it takes for the
drug concentration to reduce by half, which guides how often the drug should be
administered to maintain therapeutic levels.
4. A drug with a narrow therapeutic index (NTI) requires which of the following clinical
interventions?
A. Frequent therapeutic drug monitoring (TDM).
, B. Dosing only on an as-needed (PRN) basis.
C. Administration only via the intravenous route.
D. Strict avoidance of all generic formulations.
Answer: A
Conceptual Explanation: NTI drugs have a small window between therapeutic and toxic
doses; therefore, monitoring blood levels is essential to ensure safety and efficacy.
5. In a patient with a Creatinine Clearance (CrCl) of 25 mL/min, the provider should consider
which adjustment for a renally excreted drug?
A. Decrease the dose or lengthen the dosing interval.
B. Increase the dose to compensate for poor absorption.
C. Switch to an oral route to slow systemic entry.
D. No adjustment is necessary until CrCl is below 15 mL/min.
Answer: A
Conceptual Explanation: Decreased renal function reduces the clearance of drugs
eliminated by the kidneys, necessitating dose reductions or increased intervals to prevent
accumulation and toxicity.
6. What is the mechanism of action of ACE inhibitors in the treatment of hypertension?
A. Inhibiting the conversion of Angiotensin I to Angiotensin II.
B. Blocking the binding of Angiotensin II to AT1 receptors.
